EMA Aug 19, 2022 In Brief This Week: Genprex, Strata Oncology, Bristol Myers Squibb, Turning Point Therapeutics Aug 17, 2022 Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma Jul 25, 2022 EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca Jul 25, 2022 Gilead's Tecartus Gets EMA CHMP Recommendation in Advanced ALL Jul 22, 2022 Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma Jul 18, 2022 Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer Jun 24, 2022 EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients Jun 24, 2022 In Brief This Week: Helio Genomics, BeiGene, Day One, Mustang Bio, Ikena Oncology, Strata Oncology Jun 20, 2022 BMS Submits Breyanzi for European Approval as Second-Line Lymphoma Treatment May 3, 2022 Medac, Byondis Strike Commercialization Pact for HER2-Targeted Antibody-Drug Conjugate Apr 28, 2022 Janssen Seeking European Union Approval for Zejula in HRR-Positive Prostate Cancer Apr 11, 2022 NewStem Files FDA De Novo Submission, Gets CE Mark for Stem Cell Mutational Analysis Software Apr 1, 2022 In Brief This Week: Taiho Oncology, PamGene, Mursla, Autolus Therapeutics, Clovis Oncology Mar 28, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers Mar 25, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in Specific MSI-H/dMMR Tumors Mar 25, 2022 EMA's CHMP Issues Positive Recommendations for Novartis' Kymriah, Janssen's Carvykti Feb 25, 2022 CHMP Recommends Approval for Opdivo in PD-L1-Positive Esophageal, Urothelial Cancers Feb 25, 2022 CHMP Issues Positive Opinion for Immunocore's Kimmtrak as Metastatic Uveal Melanoma Treatment Jan 28, 2022 EMA's CHMP Issues Positive Opinion on BMS' Breyanzi for Lymphoma Patients Dec 28, 2021 EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer